Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 27;11(11):3024.
doi: 10.3390/jcm11113024.

Acute Coronary Syndrome in the COVID-19 Era-Differences and Dilemmas Compared to the Pre-COVID-19 Era

Ratko Lasica  1 , Lazar Djukanovic  1 , Igor Mrdovic  1 , Lidija Savic  1 , Arsen Ristic  2 , Marija Zdravkovic  3 , Dragan Simic  2 , Gordana Krljanac  1 , Dejana Popovic  2 , Dejan Simeunovic  2 , Dubravka Rajic  1 , Milika Asanin  1
Affiliations
Review

Acute Coronary Syndrome in the COVID-19 Era-Differences and Dilemmas Compared to the Pre-COVID-19 Era

Ratko Lasica et al. J Clin Med. .

Abstract

The COVID-19 pandemic has led to numerous negative implications for all aspects of society. Although COVID-19 is a predominant lung disease, in 10-30% of cases, it is associated with cardiovascular disease (CVD). The presence of myocardial injury in COVID-19 patients occurs with a frequency between 7-36%. There is growing evidence of the incidence of acute coronary syndrome (ACS) in COVID-19, both due to coronary artery thrombosis and insufficient oxygen supply to the myocardium in conditions of an increased need. The diagnosis and treatment of patients with COVID-19 and acute myocardial infarction (AMI) is a major challenge for physicians. Often the presence of mixed symptoms, due to the combined presence of COVID-19 and ACS, as well as possible other diseases, nonspecific changes in the electrocardiogram (ECG), and often elevated serum troponin (cTn), create dilemmas in diagnosing ACS in COVID-19. Given the often-high ischemic risk, as well as the risk of bleeding, in these patients and analyzing the benefit/risk ratio, the treatment of patients with AMI and COVID-19 is often associated with dilemmas and difficult decisions. Due to delays in the application of the therapeutic regimen, complications of AMI are more common, and the mortality rate is higher.

Keywords: COVID-19; acute coronary syndrome; before COVID and COVID era; dilemmas in COVID-19; myocardial injury.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1
Figure 1
Different types of ACS in COVID-19. Legend: SARS-CoV-2—severe acute respiratory syndrome coronavirus 2; ACS—acute coronary syndrome; UA—unstable angina; AMI—acute myocardial infarction; ACS-NNOCA—acute coronary syndrome with normal or near-normal coronary arteries; INOCA—ischemia with non-obstructive coronary artery disease; MINCA—myocardial infarction with normal coronary arteries; MINOCA—myocardial infarction with non-obstructive coronary artery disease; NSTEMI—non-ST elevation myocardial infarction; STEMI—ST elevation myocardial infarction.
Figure 2
Figure 2
Possible mechanisms of myocardial injury in patients with COVID-19. Legend: IL 6—interleukin 6; IL 1—interleukin 1; IL 17—interleukin 17; TNF-alpha—tumor necrosis factor-alpha; CRP—C-reactive protein; RAAS—renin–angiotensin–aldosterone system; CVD—cardiovascular disease.
See this image and copyright information in PMC

References

    1. World Health Organization WHO Coronavirus (COVID-19) Dashboard. [(accessed on 1 April 2022)]. Available online: https://COVID19.who.int/
    1. Gebhard C., Regitz-Zagrosek V., Neuhauser H.K., Morgan R., Klein S.L. Impact of sex and gender on COVID-19 outcomes in Europe. Biol. Sex Differ. 2020;11:29. doi: 10.1186/s13293-020-00304-9. - DOI - PMC - PubMed
    1. Henkens M.T.H.M., Raafs A.G., Verdonschot J.A.J., Linschoten M., van Smeden M., Wang P., van der Hooft B.H.M., Tieleman R., Janssen M.L.F., Ter Bekke R.M.A., et al. CAPACITY-COVID collaborative consortium. Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study. BMC Geriatr. 2022;22:184. doi: 10.1186/s12877-021-02673-1. - DOI - PMC - PubMed
    1. Barron E., Bakhai C., Kar P., Weaver A., Bradley D., Ismail H., Knighton P., Holman N., Khunti K., Sattar N., et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol. 2020;8:813–822. doi: 10.1016/S2213-8587(20)30272-2. - DOI - PMC - PubMed
    1. Gupta S., Hayek S.S., Wang W., Chan L., Mathews K.S., Melamed M.L., Brenner S.K., Leonberg-Yoo A., Schenck E.J., Radbel J., et al. STOP-COVID Investigators. Factors Associated With Death in Critically Ill Patients with Coronavirus Disease 2019 in the US. JAMA Intern. Med. 2020;180:1436–1447. doi: 10.1001/jamainternmed.2020.3596. - DOI - PMC - PubMed

LinkOut - more resources